| Literature DB >> 26354163 |
Mingrui Zhao1, Rose Alleva2, Hongtao Ma3, Andy G S Daniel4, Theodore H Schwartz5.
Abstract
Epilepsy affects roughly 1% of the population worldwide. Although effective treatments with antiepileptic drugs are available, more than 20% of patients have seizures that are refractory to medical therapy and many patients experience adverse effects. Hence, there is a continued need for novel therapies for those patients. A new technique called "optogenetics" may offer a new hope for these refractory patients. Optogenetics is a technology based on the combination of optics and genetics, which can control or record neural activity with light. Following delivery of light-sensitive opsin genes such as channelrhodopsin-2 (ChR2), halorhodopsin (NpHR), and others into brain, excitation or inhibition of specific neurons in precise brain areas can be controlled by illumination at different wavelengths with very high temporal and spatial resolution. Neuromodulation with the optogenetics toolbox have already been shown to be effective at treating seizures in animal models of epilepsy. This review will outline the most recent advances in epilepsy research with optogenetic techniques and discuss how this technology can contribute to our understanding and treatment of epilepsy in the future.Entities:
Keywords: Epilepsy model; Optical imaging; Optogenetic; Photostimulation
Mesh:
Substances:
Year: 2015 PMID: 26354163 PMCID: PMC4567692 DOI: 10.1016/j.eplepsyres.2015.06.010
Source DB: PubMed Journal: Epilepsy Res ISSN: 0920-1211 Impact factor: 3.045